Moderna, Inc. — Director's Dealing 2022

May 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-04-28

Reporting Person: Nader Francois (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-28	Common Stock	M	703	—	Acquired	703	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-28	Restricted Stock Units	$0	M	703	Disposed		Common Stock (703)	Direct
2022-04-28	Stock Option (Right to Buy)	$142.52	A	5415	Acquired		Common Stock (5415)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: The shares subject to this restricted stock unit award vested in full on April 28, 2022.

F3: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.